UPenn researchers found reduced absorption of Janssen’s Balversa in eligible bladder cancer patients
NEW YORK – It’s been three years since the US Food and Drug Administration agreed Janssen’s Balversa (erdafitinib) for patients with advanced bladder tumors harboring FGFR3 or FGFR2 gene alterations, however a...